C91.5 Catégorie · précision supplémentaire requise Adult T-cell lymphoma/leukemia (HTLV-1-associated)
ICD-10-CM C91.5 identifies “Adult T-cell lymphoma/leukemia (HTLV-1-associated)” as a category requiring further specificity in the FY2027 U.S. classification, effective October 1, 2026 through September 30, 2027.
Chapitre 2: Neoplasms
Instructions du code
Inclusion terms4
- Acute variant of adult T-cell lymphoma/leukemia (HTLV-1-associated)
- Chronic variant of adult T-cell lymphoma/leukemia (HTLV-1-associated)
- Lymphomatoid variant of adult T-cell lymphoma/leukemia (HTLV-1-associated)
- Smouldering variant of adult T-cell lymphoma/leukemia (HTLV-1-associated)
Instructions des niveaux supérieurs
Chapitres 2 · Neoplasms (C00-D49)
Note8
- Functional activity
- All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
- Morphology [Histology]
- Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
- Primary malignant neoplasms overlapping site boundaries
- A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
- Malignant neoplasm of ectopic tissue
- Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
C81-C96 · Malignant neoplasms of lymphoid, hematopoietic and related tissue (C81-C96)
C91 · Lymphoid leukemia
Excludes 11
personal history of leukemia (Z85.6)
Codes plus précis
C91.50Adult T-cell lymphoma/leukemia (HTLV-1-associated) not having achieved remissionCode facturable et spécifiqueC91.51Adult T-cell lymphoma/leukemia (HTLV-1-associated), in remissionCode facturable et spécifiqueC91.52Adult T-cell lymphoma/leukemia (HTLV-1-associated), in relapseCode facturable et spécifiqueRéférences de l’index officiel
Références de l’index officiel (2)
Leukemia, leukemic (1)
Lymphoma(of) (malignant) (1)
Historique
Historique du code
Aucune modification depuis la première observation
ModifiéInchangé
FY2016
En vigueur dès le
- Première observation
Adult T-cell lymphoma/leukemia (HTLV-1-associated)
Catégorie — choisir un code plus précis
CDC/NCHS · FY2016Toutes les éditions (19)
| Toutes les éditions | En vigueur dès le | Historique du code |
|---|---|---|
| FY2016 | 2015-10-01 | Première observation |
| FY2017 | 2016-10-01 | Aucun changement tabulaire |
| FY2018 | 2017-10-01 | Aucun changement tabulaire |
| FY2019 | 2018-10-01 | Aucun changement tabulaire |
| FY2020 | 2019-10-01 | Aucun changement tabulaire |
| FY2020 · April | 2020-04-01 | Aucun changement tabulaire |
| FY2021 | 2020-10-01 | Aucun changement tabulaire |
| FY2021 · 01-01 | 2021-01-01 | Aucun changement tabulaire |
| FY2022 | 2021-10-01 | Aucun changement tabulaire |
| FY2022 · 04-01 | 2022-04-01 | Aucun changement tabulaire |
| FY2023 | 2022-10-01 | Aucun changement tabulaire |
| FY2023 · 04-01 | 2023-04-01 | Aucun changement tabulaire |
| FY2024 | 2023-10-01 | Aucun changement tabulaire |
| FY2024 · 04-01 | 2024-04-01 | Aucun changement tabulaire |
| FY2025 | 2024-10-01 | Aucun changement tabulaire |
| FY2025 · 04-01 | 2025-04-01 | Aucun changement tabulaire |
| FY2026 | 2025-10-01 | Aucun changement tabulaire |
| FY2026 · April | 2026-04-01 | Aucun changement tabulaire |
| FY2027 | 2026-10-01 | Aucun changement tabulaire |
Explorez les codes plus précis de cette catégorie. La vérification du référentiel ne confirme pas la pertinence clinique et ne garantit pas le remboursement.